% | $
Quotes you view appear here for quick access.

GameStop Corp. Message Board

sam_0534 187 posts  |  Last Activity: 1 hour 36 minutes ago Member since: Feb 8, 1998
  • Upcoming Events
    Apr 16, 2015 11:00 AM EST
    Blackstone First Quarter 2015 Earnings Call Read Less
    Remind me

  • Business
    Top Stories
    The Blackstone Group L.P. Stock Rating Reaffirmed by Zacks (BX)
    Posted by Jim Brewer on Mar 30th, 2015 // No Comments

    The Blackstone Group L.P. (NYSE:BX)‘s stock had its “buy” rating reissued by Zacks in a research report issued on Monday. They currently have a $43.00 target price on the stock. Zacks‘s target price suggests a potential upside of 13.13% from the stock’s previous close.
    Zacks’ analyst wrote, “Blackstone’s fourth-quarter 2014 economic net income (ENI) per share surpassed the Zacks Consensus Estimate. Results benefited from a decrease in operating expenses, partially offset by lower revenues owing to decline in performance and investment fees. Improvement in assets under management (AUM) and sturdy balance sheet were the other positives. Going forward, improving economic conditions are expected to assist the company’s fund-raising ability. Also, the changing investor preference for alternative asset classes and other risk management strategies should boost top line in the forthcoming quarters. However, we remain apprehensive regarding the adverse effects of ongoing volatility in capital market and stringent regulations.”
    The Blackstone Group L.P. (NYSE:BX) traded up 1.10% on Monday, hitting $38.43. The stock had a trading volume of 1,818,226 shares. The Blackstone Group L.P. has a 52-week low of $26.56 and a 52-week high of $39.62. The stock has a 50-day moving average of $37. and a 200-day moving average of $34.. The company has a market cap of $23.15 billion and a price-to-earnings ratio of 14.90.
    The Blackstone Group L.P. (NYSE:BX) last released its earnings data on Tuesday, February 10th. The company reported $1.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.96 by $0.29. Analysts expect that The Blackstone Group L.P. will post $3.73 EPS for the current fiscal year.
    BX has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating and set a $44.00 pricetarget on shares of The Blackstone Group L.P. in a research note on Monday. Analysts at Barclays raised their price target on shares of The Blackstone Group L.P. from $41.00 to $43.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. Analysts at Keefe, Bruyette & Woods raised their price target on shares of The Blackstone Group L.P. from $39.00 to $41.00 in a research note on Friday, January 30th. Finally, analysts at Jefferies Group raised their price target on shares of The Blackstone Group L.P. from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a buy rating, The Blackstone Group L.P. has an average rating of “Buy” and a consensus target price of $43.00.

    Sentiment: Strong Buy

  • sam_0534 by sam_0534 Mar 31, 2015 10:01 AM Flag

    4:17 pm ET
    Mar 30, 2015 DEALS
    What Biotech Bubble? Specialty Pharma Stocks Pop Again on Merger Monday
    COMMENTS (1)
    2 13

    M&A has helped drive the rally in biotech stocks in the past few years. And while many investors have grown concerned that valuations are getting too lofty, pharmaceutical companies showed that they remain willing to pay up for their targets.

    On Monday, Teva Pharmaceutical Industries Ltd.TEVA +0.35% announced that it would acquire Auspex Pharmaceuticals Inc.ASPX -0.04% for roughly $3.2 billion at a 42% premium to its closing price on Friday. Horizon Pharma HZNP +2.15% PLC announced that it would purchase Hyperion Therapeutics for $955.7 million in cash, at a price just 7.6% premium over its closing price Friday but roughly 55% above its price one month ago.

    The deals announced Monday show how M&A is both reshaping the pharmaceutical industry and rapidly responding to it. Midsize and large pharmaceutical companies have struggled to refill their product pipelines as many of their biggest cash-generating drugs come off patent.

    Both Auspex and Hyperion develop so-called orphan drugs – medicines approved by the U.S. Federal and Drug Administration to treat rare diseases. Companies that manufacture such drugs are able to charge six-figure annual prices for them and receive seven years of patent protection from the FDA compared to the typical five years for other drugs. In early March, AbbVie Inc.ABBV +0.14% announced a $21 billion deal to buy Pharmacyclics PCYC +0.01%, a company that manufactures orphan drugs. At the time, investors were concerned about the steep price paid by AbbVie.

    Shares of a number of orphan-drug makers jumped Monday on all the deal making. Atara Biotherapeutics, Inc., Concert Pharmaceuticals CNCE 0.00%, Inc., and Retrophin

    Sentiment: Buy

  • that one trade was an old trade..they often show no prints trades AH..Fidleity quoting 38.40 bid 38.48 ask..Quote
    Pre-market Quote
    Historical Quote
    Option Chain
    Basic Chart
    Interactive Chart
    Company Headlines
    Press Releases
    Market Stream
    Analyst Research
    Guru Analysis
    Stock Report
    Stock Consultant
    Stock Comparison
    Call Transcripts
    Annual Report
    Income Statement
    SEC Filings
    Short Interest
    Dividend History
    Ownership Summary
    Institutional Holdings
    (SEC Form 4)
    Save Stocks
    Mar. 30, 2015 Market Close: $ 38.41 Pre-Market Charts | After Hours Charts
    View most recent trades for the selected time period:
    After Hours Volume: After Hours High: After Hours Low:
    212,988 $ 38.66
    (17:02:42 PM) $ 37.7029
    (17:24:50 PM)

    Trade Detail

    Most Active in the After-Hours
    After Hours Time (ET) After Hours Price After Hours Share Volume
    18:47 $ 38.41 20
    18:47 $ 38.41 34
    18:47 $ 38.41 34
    18:33 $ 38.41 16,910
    17:24 $ 37.7029 Low 6,600
    17:14 $ 38.579 300
    17:02 $ 38.66 High 10
    17:02 $ 38.66 High 90

    Sentiment: Strong Buy

  • "We are excited with the positive topline data results of the Phase I studies utilizing formulations and dosages of our Rexista™ Oxycodone XR product candidate, and we look forward to the FDA’s guidance on our IND filing on Rexista™ Oxycodone XR, and on our Pre-IND submission for Regabatin™" stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. "We believe that our abuse deterrent technology has the potential to positively differentiate Rexista™ from other abuse deterrent technologies of which we are aware, and that it represents an important step towards helping patients manage their pain safely. For both Rexista™ and Regabatin™, we plan to move forward, subject to FDA guidance, into Phase III trials. We also plan to explore potential strategic business development relationships for these novel product candidates."

    Sentiment: Strong Buy

  • sam_0534 by sam_0534 Mar 30, 2015 2:45 PM Flag

    02:42 PM EDT, 03/30/2015 (MT Newswires) -- The Blackstone Group L.P(BX) shares inched higher in trading Monday on a report it closed the institutional portion of its latest fund with $14.5 billion in committed capital.

    Marketwatch, citing people familiar with the matter, reported Blackstone plans to use the money to make investments around the world that may be more risky but provide the potential for better returns. Blackstone plans to raise $1.3 billion more from retail investors, according to the report. The fund, Blackstone Real Estate Partners VII, will have $15.8 billion.

    Recently, BX was up on light volume of 2.4 million shares. Average daily volume is 4.1 million shares.

    Price: 38.70, Change: +0.69, Percent Change: +1.80

    Sentiment: Buy

  • The Blackstone Group L.P. (BX) (Previous Close: $38.01, Get Quote) (Ratings, Earnings and Dividend History)
    The Blackstone Group L.P. (NYSE:BX) had its "buy" rating reaffirmed by analysts at Deutsche Bank ( ). They now have a $44.00 price target on the stock. 15.8% upside from the previous close of $38.01. Tweet This.

    Sentiment: Strong Buy

43.07+0.30(+0.70%)11:13 AMEDT